WALTHAM, Mass., September 3, 2025-- Mercy BioAnalytics, Inc., a pioneer in extracellular vesicle-based liquid biopsies for the early detection of cancer, today announced the closing of a $59 million series B financing. The round was co-led by Novalis and Sozo Ventures, with participation from Perceptive Xontogeny Venture Fund, American Cancer Society BrightEdge and iSelect Fund, as well as funds committed to women's health and leadership including Portfolia, Avestria Ventures, and Mindshift Capital.

马萨诸塞州沃尔瑟姆，2025年9月3日——Mercy BioAnalytics, Inc. 是一家致力于通过细胞外囊泡液体活检实现癌症早期检测的先锋企业，今日宣布完成了5900万美元的B轮融资。本轮融资由Novalis和Sozo Ventures共同领投，参与者包括Perceptive Xontogeny风险基金、美国癌症协会BrightEdge、iSelect基金，以及专注于女性健康与领导力的投资机构，如Portfolia、Avestria Ventures和Mindshift Capital。

The round also included significant participation from strategic investors including Hologic, Bruker Scientific, and Labcorp..

本轮融资还获得了包括Hologic、布鲁克科学公司和Labcorp在内的战略投资者的大力支持。

Coincident with the financing, Mercy is pleased to welcome Rob Freelen to the Board of Directors. A Managing Director and investment partner at Sozo Ventures, Mr. Freelen brings a wealth of experience as a seasoned Director, successful entrepreneur and former executive at Silicon Valley Bank. 'Sozo is proud to co-lead this round and help usher in a new generation of cancer diagnostics with the potential to save lives at scale.'.

在融资的同时，Mercy 很高兴地欢迎 Rob Freelen 加入董事会。作为 Sozo Ventures 的董事总经理和投资合伙人，Freelen 先生带来了丰富的经验，他是一位资深董事、成功的企业家，也曾担任硅谷银行的高管。Sozo 很荣幸能够共同领投这一轮，并帮助推动新一代癌症诊断技术的发展，这项技术有潜力大规模挽救生命。

The financing will support the commercialization of Mercy's blood-based ovarian cancer test portfolio, designed to detect ovarian cancer at earlier, more treatable stages across multiple indications. The Mercy Halo ovarian cancer screening test exhibits unprecedented sensitivity and specificity for the detection of pre-clinical high grade serous ovarian carcinoma in post-menopausal women based on a blinded evaluation of samples from a randomized controlled trial..

这笔资金将支持Mercy基于血液的卵巢癌检测产品组合的商业化，该组合旨在在多个适应症中更早、更可治疗的阶段检测卵巢癌。根据对来自随机对照试验样本的盲法评估，Mercy Halo卵巢癌筛查测试在绝经后女性中检测临床前高级别浆液性卵巢癌方面表现出前所未有的灵敏度和特异性。

The funds will additionally enable the expansion of the Mercy Halo portfolio, including multi-cancer and lung cancer screening tests.

这笔资金还将有助于扩展Mercy Halo产品组合，包括多癌症和肺癌筛查测试。

'This financing accelerates our efforts to bring transformative early cancer detection tests to patients and providers,' said Dawn Mattoon, Ph.D., Chief Executive Officer of Mercy. 'We are grateful for the support of our investors and proud to partner with those who share our mission to save lives and relieve suffering through the early detection of cancer.'.

“这笔资金加速了我们为患者和医疗服务提供者带来变革性的早期癌症检测测试的努力，”Mercy首席执行官Dawn Mattoon博士表示，“我们感谢投资者的支持，并为与那些和我们一样致力于通过早期癌症检测拯救生命、减轻痛苦的合作伙伴感到自豪。”

'We believe Mercy is building one of the most promising early detection platforms in oncology,' said Paul Meister, Partner at Novalis. 'Their technology addresses a critical gap in current cancer screening, and we're excited to support the team as they continue to deliver on critical regulatory, clinical, and commercial milestones.'.

“我们相信Mercy正在构建肿瘤学领域最有前途的早期检测平台之一，”Novalis合伙人保罗·梅斯特表示。“他们的技术解决了当前癌症筛查中的一个关键缺口，我们很高兴能够支持这个团队，因为他们继续在关键的监管、临床和商业里程碑上取得进展。”

About Mercy BioAnalytics

关于Mercy BioAnalytics

Mercy BioAnalytics, Inc. is on a mission to relieve suffering and save lives through the early detection of cancer. Early-stage cancer is difficult to detect, but when found, is more often amenable to curative therapy. The patented Mercy Halo™ liquid biopsy platform utilizes biomarker co-localization to interrogate highly abundant, blood-based extracellular vesicles that carry unique cancer signatures from their cell of origin.

慈悲生物分析公司（Mercy BioAnalytics, Inc.）致力于通过早期癌症检测来减轻痛苦、挽救生命。早期癌症难以检测，但一旦发现，通常更有可能通过治愈性治疗获得良好效果。该公司拥有专利的Mercy Halo™液体活检平台利用生物标志物共定位技术，分析血液中高度丰富的细胞外囊泡，这些囊泡携带来自其起源细胞的独特癌症特征。

The Mercy Halo platform is designed to detect early-stage cancer, when it is most treatable, and enhance the quality of life for cancer patients and their families. Mercy's initial focus is the early detection of ovarian and lung cancers. Ovarian cancer, the most lethal gynecological cancer, typically goes undetected until it is too late to cure.

Mercy Halo平台旨在检测早期癌症，此时癌症最可治疗，并提高癌症患者及其家人的生活质量。Mercy最初的重点是卵巢癌和肺癌的早期检测。卵巢癌是最致命的妇科癌症，通常在晚期才被发现，此时已难以治愈。

Lung cancer, the number one cancer killer globally, takes more lives than breast and prostate cancers combined..

肺癌是全球癌症死亡的头号杀手，其致死人数超过乳腺癌和前列腺癌的总和。